HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM)

CUSIP: 40434H104

Q2 2019 13F Holders as of 30 Jun 2019

Type / Class
Equity / COM
Total 13F shares
12,939,647
Share change
-3,633
Total reported value
$21,481,000
Price per share
$1.66
Number of holders
42
Value change
-$111,587
Number of buys
18
Number of sells
20

Quarterly Holders Quick Answers

What is CUSIP 40434H104?
CUSIP 40434H104 identifies HTGM - HTG MOLECULAR DIAGNOSTICS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) as of Q2 2019

As of 30 Jun 2019, HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) was held by 42 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 12,939,647 shares. The largest 10 holders included Stonepine Capital Management, LLC, FMR LLC, PRICE T ROWE ASSOCIATES INC /MD/, VANGUARD GROUP INC, GRANAHAN INVESTMENT MANAGEMENT INC/MA, PERKINS CAPITAL MANAGEMENT INC, ROYCE & ASSOCIATES LP, BlackRock Inc., Diametric Capital, LP, and GEODE CAPITAL MANAGEMENT, LLC. This page lists 42 institutional shareholders reporting positions in this security for the Q2 2019 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.